TW514667B - Methods for production of recombinant plasmids - Google Patents

Methods for production of recombinant plasmids Download PDF

Info

Publication number: TW514667B
Authority: TW; Taiwan
Prior art keywords: cell; plastid; gene; bacterial; cells
Prior art date: 1995-10-17

Application number

TW085115998A

Other languages

English (en)

Chinese (zh)

Inventor

Mohamad A Morsey

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-17

Filing date

1996-12-24

Publication date

2002-12-21

1996-12-24 Application filed by Novartis Ag filed Critical Novartis Ag

2002-12-21 Application granted granted Critical

2002-12-21 Publication of TW514667B publication Critical patent/TW514667B/zh

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 31
238000000034 method Methods 0.000 title claims description 50
239000013612 plasmid Substances 0.000 title abstract description 7
210000004027 cell Anatomy 0.000 claims abstract description 202
230000001580 bacterial effect Effects 0.000 claims abstract description 161
108090000623 proteins and genes Proteins 0.000 claims abstract description 161
102000004169 proteins and genes Human genes 0.000 claims abstract description 52
210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 43
239000000126 substance Substances 0.000 claims abstract description 21
241000894006 Bacteria Species 0.000 claims abstract description 16
239000002207 metabolite Substances 0.000 claims abstract description 12
231100000331 toxic Toxicity 0.000 claims abstract description 10
230000002588 toxic effect Effects 0.000 claims abstract description 10
210000002706 plastid Anatomy 0.000 claims description 230
102000004190 Enzymes Human genes 0.000 claims description 54
108090000790 Enzymes Proteins 0.000 claims description 53
238000011049 filling Methods 0.000 claims description 40
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 26
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 25
229960003767 alanine Drugs 0.000 claims description 19
239000001963 growth medium Substances 0.000 claims description 19
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 18
230000015572 biosynthetic process Effects 0.000 claims description 15
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 9
210000002421 cell wall Anatomy 0.000 claims description 8
230000004083 survival effect Effects 0.000 claims description 7
239000004472 Lysine Substances 0.000 claims description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
239000002609 medium Substances 0.000 claims description 6
101150102210 murF gene Proteins 0.000 claims description 6
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 4
101150040714 MB gene Proteins 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 3
230000002441 reversible effect Effects 0.000 claims description 3
108010016626 Dipeptides Proteins 0.000 claims description 2
101150084044 P gene Proteins 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
150000004804 polysaccharides Polymers 0.000 claims description 2
231100000419 toxicity Toxicity 0.000 claims description 2
230000001988 toxicity Effects 0.000 claims description 2
210000004102 animal cell Anatomy 0.000 claims 5
229930182847 D-glutamic acid Natural products 0.000 claims 3
238000012258 culturing Methods 0.000 claims 3
101710166307 Protein lines Proteins 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
230000003197 catalytic effect Effects 0.000 claims 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
238000004064 recycling Methods 0.000 claims 1
210000000349 chromosome Anatomy 0.000 abstract description 20
230000002759 chromosomal effect Effects 0.000 abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 abstract description 11
108020004999 messenger RNA Proteins 0.000 abstract description 7
229920001184 polypeptide Polymers 0.000 abstract description 6
102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
241000206602 Eukaryota Species 0.000 abstract description 3
230000004075 alteration Effects 0.000 abstract description 3
230000003834 intracellular effect Effects 0.000 abstract description 2
230000001225 therapeutic effect Effects 0.000 abstract description 2
108020004414 DNA Proteins 0.000 description 93
101150034814 F gene Proteins 0.000 description 47
238000001415 gene therapy Methods 0.000 description 22
241000588724 Escherichia coli Species 0.000 description 20
229940024606 amino acid Drugs 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
230000003053 immunization Effects 0.000 description 19
238000002649 immunization Methods 0.000 description 19
235000018102 proteins Nutrition 0.000 description 15
230000002079 cooperative effect Effects 0.000 description 14
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
239000012634 fragment Substances 0.000 description 13
230000037430 deletion Effects 0.000 description 12
238000012217 deletion Methods 0.000 description 12
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 11
108010013639 Peptidoglycan Proteins 0.000 description 11
230000012010 growth Effects 0.000 description 10
230000000295 complement effect Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
229960000723 ampicillin Drugs 0.000 description 8
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
238000011144 upstream manufacturing Methods 0.000 description 8
238000004113 cell culture Methods 0.000 description 7
229940113082 thymine Drugs 0.000 description 7
230000035899 viability Effects 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
230000006229 amino acid addition Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
108010041525 Alanine racemase Proteins 0.000 description 5
101150013191 E gene Proteins 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
238000001890 transfection Methods 0.000 description 5
NMWSKOLWZZWHPL-UHFFFAOYSA-N 3-chlorobiphenyl Chemical compound ClC1=CC=CC(C=2C=CC=CC=2)=C1 NMWSKOLWZZWHPL-UHFFFAOYSA-N 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
101001082832 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Pyruvate carboxylase 2 Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
210000003578 bacterial chromosome Anatomy 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
229930182830 galactose Natural products 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
-1 Val Amino acid Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
230000006801 homologous recombination Effects 0.000 description 3
238000002744 homologous recombination Methods 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
239000005022 packaging material Substances 0.000 description 3
210000001236 prokaryotic cell Anatomy 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
229930195715 D-glutamine Natural products 0.000 description 2
101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
101150050863 T gene Proteins 0.000 description 2
101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 2
101150044453 Y gene Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000003031 feeding effect Effects 0.000 description 2
101150004979 flmA gene Proteins 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
101150048892 parB gene Proteins 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940081066 picolinic acid Drugs 0.000 description 2
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
101150084750 1 gene Proteins 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100292867 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) murE gene Proteins 0.000 description 1
206010061765 Chromosomal mutation Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
229930195713 D-glutamate Natural products 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
101710126486 Envelope glycoprotein D Proteins 0.000 description 1
101710126496 Envelope glycoprotein I Proteins 0.000 description 1
101150067056 Epsilon gene Proteins 0.000 description 1
PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108091033454 Hok/sok system Proteins 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
GMKMEZVLHJARHF-WHFBIAKZSA-N LL-2,6-diaminopimelic acid Chemical compound OC(=O)[C@@H](N)CCC[C@H](N)C(O)=O GMKMEZVLHJARHF-WHFBIAKZSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CMSYVPIXXGNYEG-RTRLPJTCSA-N N'-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical compound CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CMSYVPIXXGNYEG-RTRLPJTCSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
101710177166 Phosphoprotein Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000607768 Shigella Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000008262 antibiotic resistance mechanism Effects 0.000 description 1
JGGLZQUGOKVDGS-VYTIMWRQSA-N aspartate semialdehyde Chemical compound O[C@@H]1[C@@H](NC(=O)C)CO[C@H](CO)[C@H]1O[C@@H]1[C@@H](NC(C)=O)[C@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O)[C@@H](O)[C@H](CO[C@@H]3[C@H]([C@H](O[C@@H]4[C@H]([C@H](O)[C@@H](O)[C@H](CO)O4)O)[C@@H](O)[C@H](CO)O3)O)O2)O)[C@H](CO)O1 JGGLZQUGOKVDGS-VYTIMWRQSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008618 cell wall macromolecule catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000001909 effect on DNA Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
101150091425 fimB gene Proteins 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
101150072105 hok gene Proteins 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011090 industrial biotechnology method and process Methods 0.000 description 1
238000009655 industrial fermentation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229910052750 molybdenum Inorganic materials 0.000 description 1
239000011733 molybdenum Substances 0.000 description 1
101150038355 murE2 gene Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940023146 nucleic acid vaccine Drugs 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
101150074154 pe gene Proteins 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000007639 printing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108700014590 single-stranded DNA binding proteins Proteins 0.000 description 1
101150039622 so gene Proteins 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
UPPMZCXMQRVMME-UHFFFAOYSA-N valethamate Chemical compound CC[N+](C)(CC)CCOC(=O)C(C(C)CC)C1=CC=CC=C1 UPPMZCXMQRVMME-UHFFFAOYSA-N 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
101150069452 z gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression

Landscapes

Genetics & Genomics (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)

TW085115998A 1995-10-17 1996-12-24 Methods for production of recombinant plasmids TW514667B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54805995A	1995-10-17	1995-10-17
US56497395A	1995-11-30	1995-11-30

Publications (1)

Publication Number	Publication Date
TW514667B true TW514667B (en)	2002-12-21

Family

ID=27068752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW085115998A TW514667B (en)	1995-10-17	1996-12-24	Methods for production of recombinant plasmids

Country Status (9)

Country	Link
US (1)	US5922583A (2)
EP (1)	EP0856059B1 (2)
JP (1)	JPH11513562A (2)
AT (1)	ATE247713T1 (2)
AU (1)	AU7208896A (2)
CA (1)	CA2232234A1 (2)
DE (1)	DE69629576T2 (2)
TW (1)	TW514667B (2)
WO (1)	WO1997014805A2 (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE1006085A3 (fr) *	1992-07-31	1994-05-10	Univ Bruxelles	Vecteur de clonage.
AU766257C (en) *	1998-05-07	2004-06-03	Universite Libre De Bruxelles	Cytotoxin-based biological containment
WO2000028048A1 (en) *	1998-11-09	2000-05-18	Genecare Development Aps	Novel plasmids for use in medicine and method of producing same
EP1135025B1 (en) *	1998-12-02	2007-04-25	University of Maryland, Baltimore	Plasmid maintenance system for antigen delivery
US6413768B1 (en)	1998-12-02	2002-07-02	University Of Maryland	Expression plasmids
US8076130B2 (en) *	1998-12-02	2011-12-13	University Of Maryland, Baltimore	Plasmid maintenance system for antigen delivery
US6423545B1 (en) *	1999-07-08	2002-07-23	Albert Einstein College Of Medicine Of Yeshiva University	Unmarked deletion mutants of mycobacteria and methods of using same
EP1111061A1 (en) *	1999-12-20	2001-06-27	Universite Libre De Bruxelles	Double selection vector
US9012141B2 (en) *	2000-03-27	2015-04-21	Advaxis, Inc.	Compositions and methods comprising KLK3 of FOLH1 antigen
US8470580B2 (en) *	2001-02-23	2013-06-25	Universite Libre De Bruxelles	Method for the selection of recombination clones comprising a sequence encoding an antidote protein to a toxic molecule
US7396822B2 (en) *	2001-05-24	2008-07-08	Vaxiion Therapeutics, Inc.	Immunogenic minicells and methods of use
US20030194798A1 (en) *	2001-05-24	2003-10-16	Surber Mark W.	Minicell compositions and methods
US20030224369A1 (en) *	2002-02-25	2003-12-04	Surber Mark W.	Reverse screening and target identification with minicells
US20030207833A1 (en) *	2002-02-25	2003-11-06	Neil Berkley	Pharmaceutical compositions with minicells
US20030224444A1 (en) *	2002-02-25	2003-12-04	Sabbadini Roger A.	Antibodies to native conformations of membrane proteins
US20050260585A1 (en) *	2002-03-19	2005-11-24	Cedric Szpirer	Poison/antidote genetic systems for the selection of genetically modified eucaryote cells or organisms
US20040005700A1 (en) *	2002-05-28	2004-01-08	Surber Mark W.	Poroplasts
US9309518B2 (en)	2002-09-03	2016-04-12	Universite Libre De Bruxelles	Reversible, parallel and multitask cloning method and kit
WO2004022745A2 (en) *	2002-09-03	2004-03-18	Universite Libre De Bruxelles	Reversible, parallel and multitask cloning method and kit
GB0327056D0 (en) *	2003-11-20	2003-12-24	Cobra Biolog Ltd	Plasmid maintenance
WO2006055024A2 (en) *	2004-04-05	2006-05-26	Vaxiion Therapeutics, Inc.	Minicells as vaccines
US8906664B2 (en)	2004-08-13	2014-12-09	The Trustees Of The University Of Pennsylvania	Methods for constructing antibiotic resistance free vaccines
TWI311152B (en) *	2004-09-17	2009-06-21	Boehringer Ingelheim Rcv Gmbh & Co K	Host-vector system for antibiotic-free cole1 plasmid propagation
CN1912127B (zh) *	2005-08-08	2011-05-25	百瑞全球有限公司	一种大肠杆菌表达载体及其应用
EP2152889B1 (en)	2007-05-29	2017-03-15	Nature Technology Corporation	Vectors and methods for genetic immunization
US20120135033A1 (en) *	2008-05-19	2012-05-31	Anu Wallecha	Multiple delivery system for heterologous antigens
US9017660B2 (en)	2009-11-11	2015-04-28	Advaxis, Inc.	Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en)	2008-05-19	2017-05-16	Advaxis, Inc.	Dual delivery system for heterologous antigens
US20110129499A1 (en) *	2008-05-19	2011-06-02	Paulo Maciag	Dual delivery system for heterologous antigens
US10016617B2 (en)	2009-11-11	2018-07-10	The Trustees Of The University Of Pennsylvania	Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2498808A4 (en) *	2009-11-11	2014-01-08	Advaxis	COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US9226958B2 (en)	2010-10-01	2016-01-05	University Of Georgia Research Foundation, Inc.	Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
ES2720659T3 (es)	2011-02-15	2019-07-23	Vaxiion Therapeutics Llc	Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
AU2012229218B2 (en)	2011-03-11	2017-03-02	Advaxis, Inc.	Listeria-based adjuvants
CN104411327A (zh)	2012-03-12	2015-03-11	阿德瓦希斯公司	李斯特菌疫苗治疗以后的抑制细胞功能抑制
US9550998B2 (en)	2012-08-29	2017-01-24	Nature Technology Corporation	DNA plasmids with improved expression
US20150322439A1 (en)	2012-11-19	2015-11-12	Nature Technology Corporation	Replicative minicircle vectors with improved expression
WO2015024855A1 (en)	2013-08-19	2015-02-26	Syngulon Sa	Controlled growth of microorganisms
WO2019057774A1 (en)	2017-09-19	2019-03-28	Deutsches Krebsforschungszentrum	NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
EP3456821B2 (en)	2017-09-19	2024-01-24	Deutsches Krebsforschungszentrum	Non-integrating dna vectors for the genetic modification of cells
US11932672B2 (en)	2017-12-19	2024-03-19	Syngulon S.A.	Fermentation process
WO2019183248A1 (en)	2018-03-21	2019-09-26	Nature Technology Corporation	Viral and non-viral nanoplasmid vectors with improved production
WO2025160245A1 (en)	2024-01-25	2025-07-31	Aldevron, L.L.C.	Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en)	2024-05-03	2025-11-06	Aldevron, L.L.C.	Bacterial host strains
WO2026076187A1 (en)	2024-10-03	2026-04-09	Aldevron, L.L.C.	Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4190495A (en) *	1976-09-27	1980-02-26	Research Corporation	Modified microorganisms and method of preparing and using same
US4968619A (en) *	1976-09-27	1990-11-06	Research Corporation	Modified microorganisms and method of preparing and using same
US4550081A (en) *	1980-05-19	1985-10-29	The Board Of Trustees Of The Leland Stanford Jr. University	Non-reverting salmonella
US4837151A (en) *	1980-05-19	1989-06-06	The Board Of Trustees Of The Leland Stanford Junior University, Stanford University	Live vaccines comprising two mutations and foreign antigen
US5077044A (en) *	1980-05-19	1991-12-31	The Board Of Trustees Of The Leland Stanford Jr. University	Novel non-reverting shigella live vaccines
US4735801A (en) *	1982-09-07	1988-04-05	Board Of Trustees Of Leland Stanford Jr. University	Novel non-reverting salmonella live vaccines
US5210035A (en) *	1980-05-19	1993-05-11	Board Of Trustees Of Leland Stanford Jr. University	Non-reventing live vaccines
US4888170A (en) *	1981-10-22	1989-12-19	Research Corporation	Vaccines obtained from antigenic gene products of recombinant genes
US5702916A (en) *	1982-09-16	1997-12-30	Gx Biosystems A/S	Biological Containment
DK410783D0 (da) *	1982-09-16	1983-09-09	Benzon A Salfred	Fremgangsmade til stabilisering af plasmider
FR2568891B1 (fr) *	1984-08-09	1988-05-27	Transgene Sa	Procede de preparation d'une souche, notamment de levure, transformee par un vecteur d'expression, qui peut etre cultivee sur un milieu complet sans pression de selection et souche ainsi obtenue
DK594084A (da) *	1984-12-12	1986-06-13	Novo Industri As	Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
GB2177097A (en) *	1985-06-18	1987-01-14	Genencor Inc	Stable maintenance of nucleic acid in recombinant cells
DK275685D0 (da) *	1985-06-18	1985-06-18	Benzon As Alfred	Stabilisering af biologiske systemer
US5387744A (en) *	1987-06-04	1995-02-07	Washington University	Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) *	1987-06-04	1988-11-15	Molecular Eng Ass	Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) *	1987-06-04	1994-03-15	Washington University	Avirulent microbes and uses therefor: salmonella typhi
ATE121785T1 (de) *	1987-10-07	1995-05-15	Univ Washington	Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
WO1990002484A1 (en) *	1988-09-06	1990-03-22	Washington University	Oral immunization by transgenic plants
EP0465560B1 (en) *	1989-03-31	1996-06-05	Washington University	VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
IL93957A0 (en) *	1989-03-31	1990-12-23	Univ Washington	Bordetella outer membrane proteins,their use in vaccines and their expression
WO1990011688A1 (en) *	1989-03-31	1990-10-18	Washington University	Avirulent microbes and uses therefor
US5399346A (en) *	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
EP0500699B1 (en) *	1989-11-03	1998-06-10	Washington University	Cross-protective salmonella vaccines
ATE177787T1 (de) *	1990-11-21	1999-04-15	Univ Washington	Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe
AU6705594A (en) *	1993-04-15	1994-11-08	Washington University	Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation

1996
- 1996-10-16 US US08/732,612 patent/US5922583A/en not_active Expired - Fee Related
- 1996-10-17 CA CA002232234A patent/CA2232234A1/en not_active Abandoned
- 1996-10-17 JP JP9515377A patent/JPH11513562A/ja not_active Ceased
- 1996-10-17 EP EP96933294A patent/EP0856059B1/en not_active Expired - Lifetime
- 1996-10-17 DE DE69629576T patent/DE69629576T2/de not_active Expired - Fee Related
- 1996-10-17 AU AU72088/96A patent/AU7208896A/en not_active Abandoned
- 1996-10-17 WO PCT/CA1996/000693 patent/WO1997014805A2/en not_active Ceased
- 1996-10-17 AT AT96933294T patent/ATE247713T1/de not_active IP Right Cessation
- 1996-12-24 TW TW085115998A patent/TW514667B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5922583A (en)	1999-07-13
CA2232234A1 (en)	1997-04-24
DE69629576D1 (de)	2003-09-25
ATE247713T1 (de)	2003-09-15
WO1997014805A2 (en)	1997-04-24
EP0856059B1 (en)	2003-08-20
AU7208896A (en)	1997-05-07
DE69629576T2 (de)	2004-06-24
JPH11513562A (ja)	1999-11-24
WO1997014805A3 (en)	1997-06-12
EP0856059A1 (en)	1998-08-05

Legal Events

Date	Code	Title	Description
2003-04-30	GD4A	Issue of patent certificate for granted invention patent
2006-12-11	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TW514667B (en)	2002-12-21	Methods for production of recombinant plasmids
US7871604B1 (en)	2011-01-18	Recombinant bacterial vaccine system with environmentally limited viability
JP3976685B2 (ja)	2007-09-19	タンパク質分泌のためのＣｌｙＡ溶血素の使用
Song et al.	2014	Chromosomal insertions in the Lactobacillus casei upp gene that are useful for vaccine expression
JPH0771483B2 (ja)	1995-08-02	高収量の組換え産物の産生宿主体
AU2036400A (en)	2000-06-19	Plasmid maintenance system for antigen delivery
JPH0691827B2 (ja)	1994-11-16	新規ベクタ−プラスミド
US20030202989A1 (en)	2003-10-30	Use of toxin peptides and/or affinity handles for delivering compounds into cells
CA2231784C (en)	2010-06-22	Plasmid stabilization
PT97081B (pt)	1998-07-31	Processo para a preparacao de vectores bacterianos
US20120100616A1 (en)	2012-04-26	Method of double crossover homologous recombination in clostridia
Loeffler et al.	2006	Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes
Bauer et al.	2005	Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids
ZA200105383B (en)	2002-02-25	Plasmid Maintenance System for antigen delivery.
JP2019532659A (ja)	2019-11-14	免疫寛容誘導性ｄｎａワクチン
CN101128480A (zh)	2008-02-20	含有缺损的鞭毛蛋白基因的革兰氏阳性菌细胞、基于鞭毛蛋白的融合蛋白以及从液体中除去金属离子的用途
CN120530196A (zh)	2025-08-22	一种无抗微质粒及其制备方法和应用
EP1268823B1 (en)	2007-11-07	Methods and cells for expression of recombinant protein products
JPH0576376A (ja)	1993-03-30	修飾されたトランスポゾンによるｄｎａの挿入
CA2726293C (en)	2017-02-28	Non-hemolytic clya for excretion of proteins
JP2693948B2 (ja)	1997-12-24	侵入性微生物
WO2001053474A2 (en)	2001-07-26	Flavobacterium heparinum expression system
US8076130B2 (en)	2011-12-13	Plasmid maintenance system for antigen delivery
WO1986003779A1 (fr)	1986-07-03	Vecteur de secretion de polypeptides, micro-organismes transformes par ledit vecteur, et procede de preparation de polypeptides avec lesdits micro-organismes
Hoshino et al.	1990	Genetic analysis of the Pseudomonas aeruginosa PAO high-affinity branched-chain amino acid transport system by use of plasmids carrying the bra genes